Author: Caribou Biosciences, Inc.

Posted Date:

March 31, 2026

Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy

Caribou Biosciences, Inc.

March 31, 2026
Caribou Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Caribou Biosciences, Inc.

March 5, 2026
Caribou Biosciences to Participate in Upcoming Investor Conferences

Caribou Biosciences, Inc.

February 12, 2026
Caribou Biosciences Announces Late-Breaking Presentations at the 2026 Tandem Meetings of ASTCT® and CIBMTR®

Caribou Biosciences, Inc.

February 4, 2026